Compare LABT & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LABT | MTNB |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.6M |
| IPO Year | 2026 | 2014 |
| Metric | LABT | MTNB |
|---|---|---|
| Price | $0.84 | $3.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 638.8K | 483.2K |
| Earning Date | 11-18-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $0.15 |
| 52 Week High | $6.85 | $3.05 |
| Indicator | LABT | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 26.61 | 84.84 |
| Support Level | N/A | $0.40 |
| Resistance Level | $2.13 | N/A |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | -0.10 | 0.29 |
| Stochastic Oscillator | 1.78 | 93.32 |
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.